Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Coverage
Among 7 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 4 have Buy rating, 1 Sell and 2 Hold. Therefore 57% are positive. Adamas Pharmaceuticals had 10 analyst reports since October 5, 2018 according to SRatingsIntel. The stock has “Neutral” rating by Bank of America on Friday, October 5. The firm earned “Underperform” rating on Tuesday, March 5 by Mizuho. The company was downgraded on Monday, November 5 by Mizuho. The rating was downgraded by Cowen & Co to “Market Perform” on Tuesday, March 5. The firm has “Buy” rating given on Tuesday, March 5 by H.C. Wainwright. On Tuesday, March 5 the stock rating was maintained by Piper Jaffray with “Buy”. The stock has “Buy” rating by Northland Capital on Tuesday, March 5. Below is a list of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) latest ratings and price target changes.
05/03/2019 Broker: Northland Capital Rating: Buy New Target: $28 Maintain
05/03/2019 Broker: H.C. Wainwright Rating: Buy New Target: $40 Maintain
05/03/2019 Broker: Piper Jaffray Rating: Buy New Target: $23 Maintain
05/03/2019 Broker: Needham Old Rating: Buy New Rating: Hold Downgrade
05/03/2019 Broker: Cowen & Co Old Rating: Outperform New Rating: Market Perform Old Target: $30 New Target: $15 Downgrade
05/03/2019 Broker: Mizuho Old Rating: Neutral New Rating: Underperform Old Target: $11 New Target: $5 Downgrade
26/02/2019 Broker: BidaskScore Rating: Hold Upgrade
13/11/2018 Broker: Leerink Swann Rating: Outperform New Target: $20 Initiates Coverage On
05/11/2018 Broker: Mizuho Old Rating: Buy New Rating: Neutral Old Target: $75 New Target: $18 Downgrade
05/10/2018 Broker: Bank of America Old Rating: Buy New Rating: Neutral Old Target: $36 New Target: $25 Downgrade
The stock decreased 1.14% or $0.09 during the last trading session, reaching $7.81. About 617,014 shares traded. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has declined 51.24% since March 17, 2018 and is downtrending. It has underperformed by 55.61% the S&P500.
Adamas Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders. The company has market cap of $214.38 million. The companyÂ’s product portfolio comprises ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with ParkinsonÂ’s disease. It currently has negative earnings. The Company’s portfolio also comprises of Namzaric capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe AlzheimerÂ’s disease.
More notable recent Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) news were published by: Nasdaq.com which released: “Mid-Morning Market Update: Markets Open Lower; Target Tops Q4 Expectations – Nasdaq” on March 05, 2019, also Nasdaq.com with their article: “AptarGroup (ATR) to Report Q4 Earnings: What’s in Store? – Nasdaq” published on February 18, 2019, Benzinga.com published: “Benzinga’s Top Upgrades, Downgrades For March 5, 2019 – Benzinga” on March 05, 2019. More interesting news about Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) were released by: Nasdaq.com and their article: “The Probable Reason Why Adamas Pharmaceuticals Inc. Is Down Big Today – Nasdaq” published on November 02, 2018 as well as Nasdaq.com‘s news article titled: “Mid-Afternoon Market Update: YY Rises After Q4 Results; Atlas Financial Shares Fall – Nasdaq” with publication date: March 05, 2019.